We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+3.21%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$340M
AUM Growth
-$182M
Cap. Flow
-$183M
Cap. Flow %
-53.98%
Top 10 Hldgs %
58.11%
Holding
39
New
6
Increased
3
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$17.9M
2
PMN icon
ProMIS Neurosciences
PMN
+$4.17M
3
VRDN icon
Viridian Therapeutics
VRDN
+$4.09M
4
UNCY icon
Unicycive Therapeutics
UNCY
+$3.44M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$3.12M

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$31.9M
2
ACLX
Arcellx
ACLX
+$26.1M
3
EOLS icon
Evolus
EOLS
+$17.9M
4
INSM icon
Insmed
INSM
+$16.8M
5
FOLD
Amicus Therapeutics
FOLD
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
1
Neurogene
NGNE
$656M
$42.1M 12.4%
1,004,291
– –
ABVX
2
Abivax
ABVX
$10.9B
$24.5M 7.22%
2,128,773
-343,415
-14% -$4.11M
PLRX icon
3
Pliant Therapeutics
PLRX
$64.4M
$21.4M 6.3%
1,910,121
-726,743
-28% -$9.09M
EOLS icon
4
Evolus
EOLS
$385M
$19M 5.58%
1,170,000
-1,281,772
-52% -$17.9M
VRDN icon
5
Viridian Therapeutics
VRDN
$2.09B
$17.1M 5.02%
750,000
+250,000
+50% +$4.09M
CYTK icon
6
Cytokinetics
CYTK
$10.5B
$16.7M 4.91%
316,000
-158,202
-33% -$8.82M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$15M 4.43%
1,299,503
-39,065
-3% -$491K
DVAX
8
DELISTED
Dynavax Technologies
DVAX
$14.8M 4.35%
1,326,234
-1,047,766
-44% -$11.5M
CNTX icon
9
Context Therapeutics
CNTX
$55.1M
$13.6M 4%
6,934,982
-484,373
-7% -$1.07M
ZURA icon
10
Zura Bio
ZURA
$516M
$13.3M 3.9%
3,263,672
-1,378,569
-30% -$5.15M
ORKA
11
Oruka Therapeutics
ORKA
$5.82B
$12.6M 3.71%
+514,659
New +$17.9M
MRUS
12
DELISTED
Merus
MRUS
$12.5M 3.68%
250,000
-273,288
-52% -$14.3M
OLMA icon
13
Olema Pharmaceuticals
OLMA
$1B
$11.9M 3.51%
1,000,000
+203,120
+25% +$2.6M
IONS icon
14
Ionis Pharmaceuticals
IONS
$8.6B
$10.2M 3.01%
255,000
-75,000
-23% -$3.49M
AUTL
15
Autolus Therapeutics
AUTL
$397M
$10.2M 3%
2,811,955
-629,712
-18% -$2.51M
URGN icon
16
UroGen Pharma
URGN
$1.86B
$9.64M 2.84%
758,786
-2,147,473
-74% -$31.9M
OPTN
17
DELISTED
OptiNose
OPTN
$8.62M 2.54%
857,409
-57,731
-6% -$842K
ACLX
18
DELISTED
Arcellx
ACLX
$8.35M 2.46%
100,000
-392,000
-80% -$26.1M
ACLX
19
PUT
DELISTED
Arcellx
ACLX
$8.35M 2.46%
+100,000
New +$6.66M
DNTH icon
20
Dianthus Therapeutics
DNTH
$5.84B
$7.53M 2.22%
275,000
-482,929
-64% -$13.5M
OTLK icon
21
Outlook Therapeutics
OTLK
$183M
$6.9M 2.03%
1,293,028
-408,482
-24% -$2.99M
JSPR icon
22
Jasper Therapeutics
JSPR
$21M
$6.06M 1.78%
322,380
-79,635
-20% -$1.59M
VYGR icon
23
Voyager Therapeutics
VYGR
$183M
$5.62M 1.65%
959,953
-641,574
-40% -$4.66M
BBOT
24
BridgeBio Oncology
BBOT
$648M
$5.22M 1.54%
500,000
– –
TCRX icon
25
TScan Therapeutics
TCRX
$48.6M
$5.06M 1.49%
1,016,375
+75,544
+8% +$456K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Great Point Partners held 39 positions worth $340M, down 35% from $522M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $183M in Q3 2024, closing 9 positions and reducing 19 holdings. Its most notable exit was Insmed, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Oruka Therapeutics worth $12.6M.

  • Great Point Partners's largest Q3 2024 buy was Oruka Therapeutics: 514,659 shares worth $12.6M.
  • Great Point Partners added most to Viridian Therapeutics in Q3 2024, an estimated $4.09M increase.
  • Great Point Partners's biggest Q3 2024 reduction was UroGen Pharma, cutting an estimated $31.9M.
  • Great Point Partners fully exited Insmed in Q3 2024, selling an estimated $16.8M.
  • Great Point Partners's ten largest holdings make up 58% of its $340M portfolio in Q3 2024.
  • Great Point Partners opened 6 new positions and closed 9 in Q3 2024.
  • Great Point Partners's portfolio value fell 35% quarter-over-quarter to $340M.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.